Swierczynski Sharon L, Epstein Jonathan I
Department of Pathology, The Johns Hopkins Hospital, Baltimore, MD 21231, USA.
Hum Pathol. 2002 May;33(5):512-7. doi: 10.1053/hupa.2002.124031.
Typical papillary hyperplasia, a recently recognized precursor lesion to low-grade papillary urothelial neoplasms, consists of undulating folds of cytologically benign urothelium. Well-developed, branching fibrovascular cores of a papillary neoplasm are not evident. We have noted lesions with the architectural pattern of papillary hyperplasia; however, the overlying urothelium demonstrated varying degrees of cytologic atypia. We identified 15 cases of atypical papillary hyperplasia (13 males, 2 females, age 55 to 92) with overlying urothelium showing cytologic atypia. Of these cases, 8 (53%) were received in consultation. Of the 15 cases, 8 exhibited overlying flat carcinoma in situ (CIS), 4 had overlying dysplasia, and 3 were transitional between papillary hyperplasia with atypia and the earliest lesions of papillary neoplasia. Of these cases, 5 patients had multiple specimens with atypical papillary hyperplasia (range, 2 to 8) over time. Concurrent to the diagnosis of atypical papillary hyperplasia, there were 25 different urothelial lesions: CIS (n = 11), papilloma (n = 1), papillary neoplasm of low malignant potential with CIS (n = 1), high-grade papillary urothelial carcinoma (n = 10; 3 with CIS), small-cell carcinoma (n = 1), and infiltrating urothelial carcinoma (n = 1). Of 11 patients with known prior history, 2 had 12 prior urothelial neoplasms (9 low-grade papillary neoplasms, 2 papillary urothelial neoplasms of low malignant potential, and 1 high-grade papillary cancer). Of 10 patients with atypical papillary hyperplasia and a minimum of 1 year of follow-up, 9 had 19 recurrences: CIS (n = 4), papilloma (n = 1), papillary neoplasm of low malignant potential (n = 1), infiltrating urothelial carcinoma (n = 3; 1 with CIS), and high-grade papillary urothelial carcinoma (n = 10; 5 with invasion and 2 with CIS). Whether the papillary hyperplasia had overlying CIS or dysplasia did not affect the correlation with urothelial neoplasms. Immunohistochemical analysis of p53 and Ki-67 expression in 8 cases demonstrated overexpression of p53 (n = 2; 1 with overlying dysplasia and 1 with overlying CIS), and Ki-67 (n = 5; 2 with overlying dysplasia and 3 with overlying CIS). Taken together, these results suggest that atypical papillary hyperplasia is most frequently associated with CIS and high-grade papillary cancer. In some cases, CIS or dysplasia may evolve into atypical papillary hyperplasia, with further progression to high-grade papillary cancer. This process may be analogous to papillary hyperplasia without cytologic atypia progressing to low-grade papillary urothelial neoplasms.
典型的乳头状增生是一种最近才被认识到的低度乳头状尿路上皮肿瘤的前驱病变,由细胞学上良性的尿路上皮的起伏褶皱组成。乳头状肿瘤中发育良好的分支纤维血管轴心并不明显。我们注意到具有乳头状增生结构模式的病变;然而,其上方的尿路上皮表现出不同程度的细胞学异型性。我们识别出15例非典型乳头状增生病例(13例男性,2例女性,年龄55至92岁),其上方的尿路上皮显示细胞学异型性。在这些病例中,8例(53%)是会诊病例。在这15例病例中,8例有上方的原位扁平癌(CIS),4例有上方的发育异常,3例处于非典型乳头状增生与乳头状肿瘤最早病变之间的过渡状态。在这些病例中,5例患者随时间有多个非典型乳头状增生标本(范围为2至8个)。在诊断非典型乳头状增生的同时,有25种不同的尿路上皮病变:CIS(n = 11)、乳头状瘤(n = 1)、伴有CIS的低度恶性潜能乳头状肿瘤(n = 1)、高级别乳头状尿路上皮癌(n = 10;3例伴有CIS)、小细胞癌(n = 1)和浸润性尿路上皮癌(n = 1)。在11例有已知既往病史的患者中,2例有12例既往尿路上皮肿瘤(9例低度乳头状肿瘤、2例低度恶性潜能乳头状尿路上皮肿瘤和1例高级别乳头状癌)。在10例有非典型乳头状增生且至少随访1年的患者中,9例有19次复发:CIS(n = 4)、乳头状瘤(n = 1)、低度恶性潜能乳头状肿瘤(n = 1)、浸润性尿路上皮癌(n = 3;1例伴有CIS)和高级别乳头状尿路上皮癌(n = 10;5例有浸润,2例伴有CIS)。乳头状增生上方是否有CIS或发育异常并不影响与尿路上皮肿瘤的相关性。对8例病例进行的p53和Ki-67表达的免疫组化分析显示p53过表达(n = 2;1例伴有上方发育异常,1例伴有上方CIS),以及Ki-67过表达(n = 5;2例伴有上方发育异常,3例伴有上方CIS)。综上所述,这些结果表明非典型乳头状增生最常与CIS和高级别乳头状癌相关。在某些情况下,CIS或发育异常可能演变为非典型乳头状增生,并进一步发展为高级别乳头状癌。这个过程可能类似于无细胞学异型性的乳头状增生发展为低度乳头状尿路上皮肿瘤。